blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2807151

EP2807151 - APOPTOSIS SIGNAL-REGULATING KINASE INHIBITOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.09.2016
Database last updated on 27.07.2024
Most recent event   Tooltip23.09.2016No opposition filed within time limitpublished on 26.10.2016  [2016/43]
Applicant(s)For all designated states
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
[2014/49]
Inventor(s)01 / NOTTE, Gregory
21 Otay Avenue
San Mateo, CA 94403 / US
 [2014/49]
Representative(s)Lumsden, Stuart Edward Henry
Marks & Clerk LLP
90 Long Acre
London WC2E 9RA / GB
[2015/47]
Former [2014/49]Lumsden, Stuart Edward Henry
Marks & Clerk LLP 90 Long Acre
GB-London WC2E 9RA / GB
Application number, filing date13703675.224.01.2013
[2015/47]
WO2013US22997
Priority number, dateUS201261591710P27.01.2012         Original published format: US 201261591710 P
[2014/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013112741
Date:01.08.2013
Language:EN
[2013/31]
Type: A1 Application with search report 
No.:EP2807151
Date:03.12.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 01.08.2013 takes the place of the publication of the European patent application.
[2014/49]
Type: B1 Patent specification 
No.:EP2807151
Date:18.11.2015
Language:EN
[2015/47]
Search report(s)International search report - published on:EP01.08.2013
ClassificationIPC:C07D233/56, C07D401/04, C07D401/14, A61K31/4436, A61K31/4164, A61P31/12
[2014/49]
CPC:
C07D401/14 (EP,CN,KR,US); A61K31/4164 (KR); A61K31/4436 (KR);
A61K31/4439 (EP,US); A61K45/06 (US); A61K9/0053 (US);
A61K9/20 (US); A61P1/16 (EP); A61P11/00 (EP);
A61P13/12 (EP); A61P19/04 (EP); A61P3/10 (EP);
A61P31/00 (EP); A61P31/12 (EP); A61P43/00 (EP);
A61P9/00 (EP); C07D213/56 (EP,US); C07D233/56 (EP,CN,KR,US);
C07D401/04 (EP,CN,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/49]
Extension statesBA31.07.2014
ME31.07.2014
TitleGerman:APOPTOSESIGNALREGULIERENDER KINASEHEMMER[2014/49]
English:APOPTOSIS SIGNAL-REGULATING KINASE INHIBITOR[2014/49]
French:INHIBITEUR DE LA KINASE RÉGULANT LES SIGNAUX DE L'APOPTOSE[2014/49]
Entry into regional phase31.07.2014National basic fee paid 
31.07.2014Designation fee(s) paid 
31.07.2014Examination fee paid 
Examination procedure31.07.2014Examination requested  [2014/49]
23.02.2015Amendment by applicant (claims and/or description)
21.05.2015Communication of intention to grant the patent
30.09.2015Fee for grant paid
30.09.2015Fee for publishing/printing paid
30.09.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.05.2015
Opposition(s)19.08.2016No opposition filed within time limit [2016/43]
Fees paidRenewal fee
27.01.2015Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  Tooltipdeleted
[2016/27]
Former [2016/25]LV18.11.2015
Cited inInternational search[A]WO2011008709  (GILEAD SCIENCES INC [US], et al) [A] 1-12 * the whole document *;
 [A]WO2012003387  (GILEAD SCIENCES INC [US], et al) [A] 1-12* the whole document *
by applicantUS2007276050
 WO2009027283
 US2011009410
    - ICHIJO, H.; NISHIDA, E.; IRIE, K.; DIJKE, P. T.; SAITOH, M.; MORIGUCHI, T.; MATSUMOTO, K.; MIYAZONO, K.; GOTOH, Y., SCIENCE, (1997), vol. 275, pages 90 - 94
    - HATTORI, K.; NAGURO, I.; RUNCHEL, C.; ICHIJO, H., CELL COMM. SIGNAL., (2009), vol. 7, pages 1 - 10
    - TAKEDA, K.; NOGUCHI, T.; NAGURO, I.; ICHIJO, H., ANNU. REV. PHARMACOL. TOXICOL., (2007), vol. 48, pages 1 - 8,27
    - NAGAI, H.; NOGUCHI, T.; TAKEDA, K.; ICHIJO, I., J. BIOCHEM. MOL. BIOL., (2007), vol. 40, pages 1 - 6
    - WATANABE ET AL., BBRC, (2005), vol. 333, pages 562 - 567
    - ZHANG ET AL., LIFE SCI, (2003), vol. 74, pages 37 - 43
    - TERADA ET AL., BBRC, (2007), vol. 364, pages 1043 - 49
    - SINGH DK; WINOCOUR P; FARRINGTON K., "Oxidative stress in early diabetic nephropathy: fueling the fire", NAT REV ENDOCRINOL, (201103), vol. 7, no. 3, pages 176 - 184
    - BROWNLEE M., "Biochemistry and molecular cell biology of diabetic complications", NATURE, (20011213), vol. 414, no. 6865, pages 813 - 820
    - MIMURA I; NANGAKU M.; 2010 NOV, "The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease", NAT REV NEPHROL, vol. 6, no. 11, pages 667 - 678
    - HUNG KY ET AL., "N- acetylcysteine-mediated antioxidation prevents hyperglycemia-induced apoptosis and collagen synthesis in rat mesangial cells", AM JNEPHROL, (2009), vol. 29, no. 3, pages 192 - 202
    - SCHAINUCK LI ET AL., "Structural-functional correlations in renal disease. Part II: The correlations", HUM PATHOL, (1970), vol. 1, pages 631 - 641
    - CHEVALIER ET AL., "Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy", KIDNEY INTERNATIONAL, (2009), vol. 75, pages 1145 - 1152
    - DE B, I ET AL., "Temporal trends in the prevalence of diabetic kidney disease in the United States", JAMA, (20110622), vol. 305, no. 24, pages 2532 - 2539
    - BERGE, JOURNAL OFPHARMACEUTICAL SCIENCE, (197701), vol. 66, no. 1
    - G.S. BANKER & C.T. RHODES,, Modern Pharmaceutics 3rd Ed., MARCEL DEKKER, INC.
    - STAMBE ET AL., "The Role ofp38 Mitogen-Activated Protein Kinase Activation in Renal Fibrosis", JAM SOC NEPHROL, (2004), vol. 15, pages 370 - 379
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.